Characterization of cell therapies from early R&D all the way through scale-up is critical to ensure that potency and mechanism of action remain unchanged. A-DOC can help by analyzing genotype and phenotype using single-cell capabilities and assessing therapy performance in a variety of functional assays. Creating a clear definition of “the product” based on multiple characteristics linked to potency and efficacy early in development ensures that process changes do not impact product function.